8-K: Sonnet BioTherapeutics Faces Nasdaq Delisting Threat Due to Share Price

Sonnet BioTherapeutics received a delisting notice from Nasdaq due to non-compliance with the minimum bid price requirement, and the company plans to request a hearing to appeal the decision.

Summary

• Sonnet BioTherapeutics Holdings, Inc. received a letter from Nasdaq on August 5, 2024, indicating that the company is not in compliance with the $1.00 minimum bid price requirement for continued listing.
• The company's stock price has been below $1.00 for the last 30 consecutive business days, triggering the delisting notice.
• Due to previous reverse stock splits with a cumulative ratio of 250 shares or more to one within the past two years, Nasdaq did not grant additional time for the company to regain compliance.
• Sonnet BioTherapeutics intends to request a hearing before the Nasdaq Hearings Panel to appeal the delisting decision and request an extension to regain compliance.
• The company plans to take steps to evidence compliance, including potentially implementing another reverse stock split.
• There is no guarantee that the panel will grant the company's request or that the company will be able to meet the minimum bid price requirement.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice and the uncertainty surrounding the company's ability to regain compliance. The potential for a reverse stock split also adds to the negative outlook.

Positives

• The company is taking immediate action by requesting a hearing to appeal the delisting notice.
• The company is exploring options, including a reverse stock split, to regain compliance with the minimum bid price requirement.
• The request for a hearing will automatically stay any suspension or delisting action pending the hearing.

Negatives

• The company's stock price has fallen below the required $1.00 minimum bid price for 30 consecutive business days.
• Nasdaq did not grant an extension due to previous reverse stock splits.
• There is no assurance that the company will be able to regain compliance or that the panel will grant the request for continued listing.

Risks

• The company faces the risk of being delisted from Nasdaq if it cannot regain compliance with the minimum bid price requirement.
• There is no guarantee that the Nasdaq Hearings Panel will grant the company's request for continued listing.
• The company may need to implement a reverse stock split, which could negatively impact shareholder value.
• The company's ability to raise capital may be impacted by the delisting threat.

Future Outlook

The company intends to request a hearing and take steps to regain compliance with the minimum bid price requirement, including potentially implementing a reverse stock split, but there is no guarantee of success.

Management Comments

• The company intends to timely request a hearing before the Panel.
• The company intends to continue to take definitive steps in an effort to evidence compliance with the Bid Price Requirement, including by effecting a reverse stock split.

Industry Context

Delisting notices are not uncommon for companies that fail to maintain minimum share price requirements, particularly in the biotechnology sector where stock prices can be volatile. This situation highlights the challenges faced by smaller companies in maintaining listing compliance.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges in maintaining Nasdaq listing compliance due to volatile stock prices.
• Companies like Agenus Inc. and Cellectar Biosciences have also faced delisting threats due to low share prices, highlighting the industry-wide issue.
• Reverse stock splits are a common strategy used by companies in this situation to regain compliance, but they can be viewed negatively by investors.

Stakeholder Impact

• Shareholders face the risk of losing their investment if the company is delisted.
• Employees may experience uncertainty about the company's future.
• The company's ability to raise capital may be impacted by the delisting threat.

Next Steps

• The company will request a hearing before the Nasdaq Hearings Panel.
• The company will seek an extension to regain compliance with the minimum bid price requirement.
• The company may implement a reverse stock split to increase its share price.

Key Dates

Keywords

delisting, Nasdaq, minimum bid price, reverse stock split, compliance, hearing, SONN, stock price